Purpose: This study aimed to identify the influence of job stress, compassion satisfaction, and resilience on depression of nurses. Methods: One hundred seventy six nurses working at one tertiary ...hospital in one metropolitan city were included. The data collection was conducted from September 1st to October 1st, 2018, using a structured, self-reported questionnaire. The collected data were analyzed using descriptive statistics, t-test, one-way ANOVA, Pearson’s correlation coefficients, and multiple regression. Results: The M±SD age of 170 subjects was 29.62±5.59. Depression had significant negative correlations with compassion satisfaction (r=-.50, p<.001) and resilience (r=-.56, p<.001), and a positive correlation with job stress (r=.42, p<.001). In the multiple regression analysis, marital status (β=-.15, p=.015), job stress (β=-.00, p<.001) and resilience (β=-5.47, p<.001) had a significant effect on depression. The explanatory power of the subject’s marital status, leisure life, job stress, compassion satisfaction, and resilience on depression was 44.1% (F=27.62, p<.001). Conclusion: The study results showed that single status, low job stress, high resilience may decrease depression of nurses. Reducing job stress and improving resilience of nurses will virtually contribute to reduce their depression that can influence on not only nurses’ health status but also their performance and qualitative caring for patients.
Objective: To compare survival outcomes between bevacizumab (BEV) and olaparib (OLA) maintenance therapy in BRCA-mutated, platinum-sensitive relapsed (PSR) high-grade serous ovarian carcinoma ...(HGSOC).
Methods: From 10 institutions, we identified HGSOC patients with germline and/or somatic BRCA1/2 mutations, who experienced platinum-sensitive recurrence between 2013 and 2019, and received second-line platinum-based chemotherapy. Patients were divided into BEV (n=29), OLA (n=83), and non-BEV/non-OLA users (n=36). The OLA and non-BEV/non-OLA users were grouped as the OLA intent group. We conducted 1:2 nearest neighbor-matching between the BEV and OLA intent groups, setting the proportion of OLA users in the OLA intent group from 65% to 100% at 5% intervals, and compared survival outcomes among the matched groups.
Results: Overall, OLA users showed significantly better progression-free survival (PFS) than BEV users (median, 23.8 vs. 17.4 months; p=0.004). Before matching, PFS improved in the OLA intent group but marginal statistical significance (p=0.057). After matching, multivariate analyses adjusting confounders identified intention-to-treat OLA as an independent favorable prognostic factor for PFS in the OLA 65P (adjusted hazard ratio aHR=0.505; 95% confidence interval CI=0.280-0.911; p=0.023) to OLA 100P (aHR=0.348; 95% CI=0.184-0.658; p=0.001) datasets. The aHR of intention-to-treat OLA for recurrence decreased with increasing proportions of OLA users. No differences in overall survival were observed between the BEV and OLA intent groups, and between the BEV and OLA users.
Conclusion: Compared to BEV, intention-to-treat OLA and actual use of OLA maintenance therapy were significantly associated with decreased disease recurrence risk in patients with BRCA-mutated, PSR HGSOC.
